Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway

Nature Cell Biology

Volumn 8, Issue 10, 2006, Pages 1053-1063

  Denoyelle, Christophe ^a   Abou Rjaily, George ^a   Bezrookove, Vladimir ^b   Verhaegen, Monique ^a   Johnson, Timothy M ^a   Fullen, Douglas R ^c   Pointer, Jenny N ^a   Gruber, Stephen B ^a   Su, Lyndon D ^c   Nikiforov, Mikhail A ^a   Kaufman, Randal J ^c   Bastian, Boris C ^b   Soengas, Maria S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN P16; PROTEIN P53;

ARTICLE; CANCER CONTROL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL ONCOGENE; CELL TRANSFORMATION; CELL VACUOLE; CONTROLLED STUDY; DNA DAMAGE; DOWNSTREAM PROCESSING; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE MUTATION; HETEROCHROMATIN; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOCYTE; NEVUS; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; SENESCENCE;

CELL AGING; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; ENDOPLASMIC RETICULUM; FIBROBLASTS; GENES, RAS; HETEROCHROMATIN; HUMANS; INFANT; MELANOCYTES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

PYRONIA TITHONUS;

EID: 33749184798     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1471     Document Type: Article

References (51)

1. Jemal, A. et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
3. Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19-20 (2003).
4. E600-associated senescence-like cell cycle arrest of human naevi. Nature 436. 720-724 (2005).
5. Strungs, I. Common and uncommon variants of melanocytic naevi. Pathology 36, 396-403 (2004).
6. INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J. Med. Genet. 36, 610-614 (1999).
7. Bastian, B. C., LeBoit, P. E. & Pinkel, D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am. J. Pathol. 157, 967-972 (2000).
8. Barnhill, R. L. et al. Atypical Spitz nevi/tumors: Lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum. Pathol. 30, 513-520 (1999).
9. Maldonado, J. L., Timmerman, L., Fridlyand, J. & Bastian, B. C. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am. J. Pathol. 164, 1783-1787 (2004).
10. Collado, M. & Serrano, M. The power and the promise of oncogene-induced senescence markers. Nature Rev. Cancer 6, 472-476 (2006).
11. Shay, J. W. & Roninson, I. B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23, 2919-2933 (2004).
12. Campisi, J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522 (2005).
13. Mallette, F. A., Goumard, S., Gaumont-Leclerc, M. F., Moiseeva, O. & Ferbeyre, G. Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23, 91-99 (2004).
14. Federovitch, C. M., Ron, D. & Hampton, R. Y. The dynamic ER: experimental approaches and current questions. Curr. Opin. Cell Biol. 17, 409-414 (2005).
15. Schroder, M. & Kaufman, R. J. The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789 (2005).
16. Lee, A. S. The glucose-regulated proteins: Stress induction and clinical applications. Trends Biochem. Sci. 26, 504-510 (2001).
17. Lassot, I. et al. ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(βTrCP) ubiquitin ligase. Mol. Cell. Biol. 21, 2192-2202 (2001).
18. Vallejo, M., Ron, D., Miller, C. P. & Habener, J. F. C/ATF, a member of the activating transcription factor family of DNA-binding proteins, dimerizes with CAAT/enhancer-binding proteins and directs their binding to cAMP response elements. Proc. Natl Acad. Sci. USA 90, 4679-4683 (1993).
19. Harding, H. P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099-1108 (2000).
20. Ron, D. & Hampton, R. Y. Membrane biogenesis and the unfolded protein response. J. Cell Biol. 167, 23-25 (2004).
21. Jamora, C., Dennert, G. & Lee, A. S. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/ C10ME. Proc. Natl Acad. Sci. USA 93, 7690-7694 (1996).
22. Romero-Ramirez, L. et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64, 5943-5947 (2004).
23. Xu, C., Bailly-Maitre, B. & Reed, J. C. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 115, 2656-2664 (2005).
24. Malumbres, M, & Barbacid, M. RAS oncogenes: The first 30 years. Nature Rev. Cancer 3, 459-465 (2003).
25. Philips, M. R. Compartmentalized signalling of Ras. Biochem. Soc. Trans. 33, 657-661 (2005).
26. Matallanas, D. et al. Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation. Mol. Cell. Biol. 26, 100-116 (2006).
27. Q61K on an INK4a-deficient background. Cancer Res. 65, 4005-4011 (2005).
28. Li, W., Zhu, T. & Guan, K. L. Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. J. Biol. Chem. 279, 37398-37406 (2004).
29. Lin, A. W. et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12, 3008-3019 (1998).
30. Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716 (2003).
31. Bauer, J. & Bastian, B. Genomic analysis of melanocytic neoplasia. Adv. Dermatol. 21, 81-99 (2005).
32. Narita, M. & Lowe, S. W. Senescence comes of age. Nature Med. 11, 920-922 (2005).
33. Sharpless, N. E. & DePinho, R. A. Cancer: Crime and punishment. Nature 436, 636-637 (2005).
34. Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
35. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
36. Collado, M. & Serrano, M. The senescent side of tumor suppression. Cell Cycle 4, 1722-1724 (2005).
37. Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003).
38. Benanti, J. A. & Galloway, D. A. Normal human fibroblasts are resistant to RAS-induced senescence. Mol. Cell. Biol. 24, 2842-2852 (2004).
39. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
40. te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J. & Joel, S. P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62, 1876-1883 (2002).
41. Ma, Y. & Hendershot, L. M. The role of the unfolded protein response in tumour development: Friend or foe? Nature Rev. Cancer 4, 966-977 (2004).
42. Li, J. & Lee, A. S. Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 6, 45-54 (2006).
43. Sriburi, R., Jackowski, S., Mori, K. & Brewer, J. W. XBP1: A link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J. Cell Biol. 167, 35-41 (2004).
44. Back, S. H., Lee, K., Vink, E. & Kaufman, R. J. Cytoplasmic IRE1α-mediated XBP1 mRNA splicing in the absence of nuclear processing and endoplasmic reticulum stress. J. Biol. Chem. 281, 18691-18706 (2006).
45. Harding, H. P. et al An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619-633 (2003).
46. Blais, J. D. et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol. Cell. Biol. 24, 7469-7482 (2004).
47. Dai, D. L., Martinka, M. & Li, G. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 1473-1482 (2005).
48. Miyauchi, H. et al. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J. 23, 212-220 (2004).
49. Hamanaka, R. B., Bennett, B. S., Cullinan, S. B. & Diehl, J. A. PERK and GCN2 contribute to eIF2α phosphorylation and cell cycle arrest after activation of the unfolded protein response pathway. Mol. Biol. Cell 16, 5493-5501 (2005).
50. Ranganathan, A. C., Zhang, L., Adam, A. P. & Aguirre-Ghiso, J. A. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 66, 1702-1711 (2006).
51. Wang, Y. et al. Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response. J. Biol. Chem. 275, 27013-27020 (2000).